DIWA

Drugs Inspector Welfare Association

ICH_Q1Q5C_EWG_WorkPlan_2024_0930.pdfICH_Q2(R2)-Q14_IWG_WorkPlan_2024_0730.pdfICH_Q2(R2)_Guideline_2023_1130.pdfICH_Q2R2Q14_IWG_Final_Concept_2023_1030.pdfQ1A(R2) Guideline.pdfQ1B Guideline.pdfQ1C Guideline.pdfQ1D Guideline.pdfQ1E Guideline.pdfQ1E Presentation.pdfQ1F_Explanatory_Note.pdfQ1F_Stability_Guideline_WHO_2018.pdfQ2R2-Q14_EWG_Business_Plan.pdfQ2R2-Q14_EWG_Concept_Paper.pdfQ2_Q14 ICH_Step_4_Presentation_2023_1106_0.pdfQ3A(R2) Guideline.pdfICH Guideline Index- Safety.xlsxICH Guidelines Index- Efficacy.xlsxICH Guidelines Index- Multidisciplinary.xlsxICH Guidelines Index- Quality.xlsxICH Q9R1_Step_4_Presentation_2023_0314_final.pdfICH Q13_Step_4_Presentation_2023_0112_0.pdfICH_Q5A(R2)_Guideline_2023_1101.pdfICH_Q5A(R2)_Step4_Presentation_2023 Final_2023_1106.pdfICH_Q9(R1)_Formality_Training_Material_2023_0929.pptxICH_Q9(R1)_Guideline_Step4_2023_0126_0.pdfICH_Q9(R1)_Hazard_ID_Part_II_Training_Material_2023_0929.pptxICH_Q9(R1)_Hazard_ID_Part_I_Training_Material_2023_0923.pptxICH_Q9(R1)_Product_Availability_Risk_Training_Material_2023_0929.pptxICH_Q9(R1)_RBDM_Training_Material_2023_0929.pptxICH_Q9(R1)_Risk_Review_Training_Material_2023_0929.pptxICH_Q9(R1)_Subjectivity_CASESTUDY_2023_0929.pptxICH_Q9(R1)_Subjectivity_Training_Materials_Part1_2023_0929.pptxICH_Q9(R1)_Subjectivity_Training_Materials_Part2_2023_0929.pptxICH_Q13_Step4_Guideline_2022_1116.pdfICH_Q14_Guideline_2023_1116_1.pdfQ2_Q14 ICH_Step_4_Presentation_2023_1106_0_1.pdfQ3B(R2) Concept Paper.pdfQ3B(R2) Guideline.pdfQ4B Guideline.pdfQ4B Presentation.pdfQ4B_Frequently Asked Questions_26.April_.pdfQ5A-R2_FinalBusinessPlan_2019_1118.pdfQ5A-R2_FinalConceptPaper_2019_1117.pdfQ6A Decision Tree.pdfQ6A Guideline.pdfQ7 Concept paper.pdfQ7 Guideline.pdfQ8(R2) Concept Paper.pdfQ8(R2) Guideline.pdfQ9-R1_Concept Paper_2020_1113.pdfQ10 Guideline.pdfQ10_Presentation.pdfQ11 Guideline.pdfQ12EWG_Step4_IntroTrainingPresentation_2020_0206.pdfQ12_Annexes_Step4_2019_1119.pdfQ12_Guideline_Step4_2019_1119.pdf